Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Deferred Taxes: 2015-2017

Historic Deferred Taxes for CytomX Therapeutics (CTMX) over the last 1 years, with Dec 2017 value amounting to -$520,000.

  • CytomX Therapeutics' Deferred Taxes was N/A to -$520,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$513,000, marking a year-over-year change of. This contributed to the annual value of -$513,000 for FY2017, which is 8650.00% down from last year.
  • Per CytomX Therapeutics' latest filing, its Deferred Taxes stood at -$520,000 for Q4 2017, which was down 2,636.84% from -$19,000 recorded in Q3 2017.
  • In the past 5 years, CytomX Therapeutics' Deferred Taxes ranged from a high of $25,000 in Q2 2017 and a low of -$520,000 during Q4 2017.
  • Its 3-year average for Deferred Taxes is -$72,000, with a median of $3,000 in 2016.
  • The largest annual percentage gain for CytomX Therapeutics' Deferred Taxes in the last 5 years was 733.33% (2017), contrasted with its biggest fall of 66.67% (2017).
  • Over the past 3 years, CytomX Therapeutics' Deferred Taxes (Quarterly) stood at $3,000 in 2015, then reached $3,000 in 2016, then skyrocketed by 733.33% to -$520,000 in 2017.
  • Its Deferred Taxes stands at -$520,000 for Q4 2017, versus -$19,000 for Q3 2017 and $25,000 for Q2 2017.